Trial Profile
A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Evofosfamide (Primary) ; Ipilimumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Threshold Pharmaceuticals
- 16 Jun 2021 Results published in the ImmunoGenesis Media Release
- 26 Mar 2021 Results assessing (n=21; Median age= 67 years) safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of combining evofosfamide and ipilimumab in patients with advanced solid tumors, published in the Clinical Cancer Research.
- 13 Jun 2017 According to a Threshold Pharmaceuticals media release, first patient has been dosed in the trial at the University of Texas MD Anderson Cancer Center.